Literature DB >> 31082771

MiR-362-3p is downregulated by promoter methylation and independently predicts shorter OS of cervical squamous cell carcinoma.

Lili Song1, Shikai Liu2, Hairong Yao1, Liang Zhang1, Ying Li1, Dongkui Xu1, Qian Li1.   

Abstract

The current study was undertaken to investigate the potential influence of methylation on miR-362-5p/3p expression and further analyzed their independent prognostic value in cervical adenocarcinoma (ADC) and squamous cell carcinoma (SCC) respectively. SiHa and CaSki cells were used as the in vitro cell model. In silico bioinformatic analysis was conducted via the combined use of the Cancer Genome Atlas-Cervical Cancer (TCGA-CESC), Starbase 3.0 and String 10.5. Results revealed that the downregulation of miR-362-5p/3p was accompanied by the infection of high-risk human papillomavirus (HR-HPV) and their expression was further decreased in HR-HPV cancer tissues. Demethylation could restore their expression. By performing Methylation-specific PCR (MSP) based on methylated or unmethylated specific primers, we confirmed that the proximal promoter region was methylated in both cell lines. Higher miR-362-3p expression might independently predict favorable overall survival (OS) in SCC patients (HR: 0.561, 95%CI: 0.354-0.889, p = 0.014), after adjustment of clinical stages, lymphovascular invasion and miR-362-5p expression. However, no prognostic value of miR-362-5p or miR-362-3p expression was observed in terms of OS in patients with ADC. Via bioinformatic analysis, we found that miR-362-3p might have an entirely different regulatory network in cervical ADC and SCC, which might help to explain the distinct prognostic value of miR-362-3p in these two histological subtypes. In summary, we infer that the methylation level of the proximal promoter region of pre-miR-362 would influence the expression of miR-362-5p/3p in cervical cancer. MiR-362-3p expression might be a specific prognostic biomarker in cervical SCC, but not in ADC.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cervical squamous cell carcinoma; Prognosis; Promoter methylation; miR-362-3p

Mesh:

Substances:

Year:  2019        PMID: 31082771     DOI: 10.1016/j.biopha.2019.108944

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  miR-362-3p suppresses ovarian cancer by inhibiting LRP8.

Authors:  Chun Li; Yi Yang; Huimin Wang; Yu Song; Huan Huang
Journal:  Transl Oncol       Date:  2021-11-26       Impact factor: 4.243

2.  A novel microRNA signature for the detection of melanoma by liquid biopsy.

Authors:  Claudia Sabato; Teresa Maria Rosaria Noviello; Anna Maria Di Giacomo; Elisabetta Ferretti; Alessia Covre; Sandra Coral; Francesca Pia Caruso; Zein Mersini Besharat; Elena Splendiani; Laura Masuelli; Cecilia Battistelli; Alessandra Vacca; Giuseppina Catanzaro; Agnese Po; Andrea Anichini; Michele Maio; Michele Ceccarelli
Journal:  J Transl Med       Date:  2022-10-15       Impact factor: 8.440

3.  MiR-362 suppresses cervical cancer progression via directly targeting BAP31 and activating TGFβ/Smad pathway.

Authors:  Shuya Yang; Yuanjie Sun; Dongbo Jiang; Jing Wang; Erle Dang; Zichao Li; Jiayi Zhou; Yuchen Lu; Jingqi Shi; Liang Tao; Jun Wang; Boquan Jin; Lianhe Zheng; Kun Yang
Journal:  Cancer Med       Date:  2020-11-19       Impact factor: 4.452

4.  A prognostic model guides surgical resection in cervical squamous cell carcinoma.

Authors:  Baiqiang Liang; Haibing Yu; Lianfang Huang; Haiqing Luo; Xiao Zhu
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

5.  Aberrant miR-362-3p is Associated with EBV-Infection and Prognosis in Nasopharyngeal Carcinoma and Involved in Tumor Progression by Targeting JMJD2A.

Authors:  Xiangyun Wang; Ping Chen
Journal:  Onco Targets Ther       Date:  2022-01-28       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.